Lilly M&A streak rolls on with purchase of DNA delivery biotech
There’s no query Eli Lilly has been probably the most lively biopharma dealmaker of latest months, however even the billions the pharma already spent on acquisitions hasn’t exhausted its urge for food.
The newest goal is California-based Engage Biologics, for which Lilly is paying $202 million. That quantity contains each an upfront payment and milestone payouts, though the businesses didn’t supply a breakdown of the financials.
Based in San Carlos, Engage is creating non-viral DNA delivery techniques that intention to beat conventional limitations related with the modality. The preclinical firm counts SciFounders, Pioneer Fund, Cal Innovation Fund, Y Combinator and the Cystic Fibrosis Foundation as seed founders. It’s additionally acquired funding from the Gates Foundation and the National Center for Advancing Translational Sciences, half of the National Institutes of Health.
With its Tethosome platform, Engage goals to beat efficiency, tolerability and redosability challenges of DNA delivery. The platform leverages engineered DNA payloads with lipid nanoparticle delivery and mRNA-encoded know-how in an effort to “enhance localization and increase expression,” in line with the discharge.
“We are excited to begin our next chapter with Lilly, which has demonstrated unmatched speed and a uniquely forward-thinking approach to genetic medicine,” Engage CEO Will Olsen mentioned in an announcement. “We believe that the combination of Engage’s platform with Lilly’s significant capabilities will meaningfully accelerate development of new genetic therapies.”
As for Lilly, the Engage buyout marks following a busy spring of dealmaking. Last month, the pharma large unveiled its $2.3 billion purchase of Ajax, a New York biotech with a clinical-stage myelofibrosis remedy. Before that, Lilly made a splash with its $3.2 billion upfront buyout of in vivo CAR-T firm Kelonia Therapeuticsamongst different latest acquisitions.
The regular stream of M&A offers outlines a core technique enjoying out on the firm: Late final 12 months, a Lilly exec instructed Fierce the pharma needed to make use of its GLP-1 windfall to turn into a “backbone of the overall innovation ecosystem all around the world.”
